- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00605332
Crux Biomedical IVC Filter - Evaluation of the Crux Inferior Vena Cava Filter System (Retrieve) (Retrieve)
August 3, 2012 updated by: Crux Biomedical
Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System - ("Retrieve")
This is an open label, non-randomized, prospective, multicenter study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
88
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients for this study must meet the following inclusion criteria to be eligible for enrollment:
- The patient is >18 years of age.
Patient is considered a candidate for the IVCF under one of the following indications:
- Proven PE
- Recurrent PE despite adequate anticoagulation
- Contraindication to anticoagulation
- Inability to achieve/maintain therapeutic anticoagulation
- Iliocaval DVT
- Large, free-floating proximal (i.e. ileofemoral) DVT
- Massive PE treated with thrombolysis/thrombectomy
- Chronic PE treated with thrombectomy
- Protection during thrombolysis for iliocaval DVT
- PE with limited cardiopulmonary reserve
- Poor compliance with anticoagulant medications
- High risk of injury worsened by anticoagulation (e.g., ataxia, falls)
- Multi-trauma patient with high risk of PE
- Surgical patients at high risk of PE
- Medical condition with high risk of PE
- Patient has a vena cava diameter of 17-28mm.
- The patient or legal guardian has been informed of the nature of the study and agrees to its provisions and has provided informed written consent.
- The patient is willing to be available for the appropriate follow-up for the duration of the study.
- The patient has suitable IVC anatomy that would allow infra-renal placement of the filter.
Exclusion Criteria:
Patients who have ANY of the following exclusion criteria are NOT eligible for the study:
The patient has one of the following conditions:
- Renal vein thrombosis
- IVC thrombosis extending to renal veins
- Duplicate IVC
- Gonadal vein thrombosis
- Requires supra-renal filter placement
- The patient has an uncontrolled infectious disease.
- The patient is at risk for aseptic PE.
- Patient has uncontrollable coagulopathy.
- Patient has an existing IVCF.
- The patient has a life expectancy of less than 6 months.
- The patient is pregnant.
- The patient has a condition that inhibits radiographic visualization of the IVC.
- The patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol.
- The patient has a known hypersensitivity to contrast which cannot be pre-treated.
- The patient's access vessels preclude safe insertion of the delivery system.
- The patient is participating in another device or drug study. Patient must have completed the follow- up phase of any previous study at least 30 days prior to enrollment into this trial. The patient may only be enrolled in this study once.
- The patient is unable and/or unwilling to cooperate with study procedures or required follow-up visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Investigative Device (Crux Biomedical IVC Filter) will be evaluated for its ability to capture thrombus for the prevention of pulmonary embolism.
|
Crux Biomedical IVC Filter
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary Efficacy Objective: To describe the clinical utility of the Crux IVCF by the following criteria: Absence of a recurrent PE and IVC thrombosis related to the Crux IVCF.
Time Frame: 30 days post implant, 30 days post retrieval. Patients with indwelling filters will return 1 and 6 months post implant procedure.
|
30 days post implant, 30 days post retrieval. Patients with indwelling filters will return 1 and 6 months post implant procedure.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary Safety Objective: To estimate the proportion of patients who experience device/procedure related complications associated with the Crux IVCF.
Time Frame: 30 days post implant procedure and 30 days post retrieval procedure. Patients with indwelling filters will return 1 and 6 months post implant procedure.
|
30 days post implant procedure and 30 days post retrieval procedure. Patients with indwelling filters will return 1 and 6 months post implant procedure.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Rosenthal, MD, Atlanta Vascular Specialists
- Study Director: Mel Schatz, Crux Biomedical
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
July 1, 2008
Study Completion (Actual)
July 1, 2009
Study Registration Dates
First Submitted
January 2, 2008
First Submitted That Met QC Criteria
January 30, 2008
First Posted (Estimate)
January 31, 2008
Study Record Updates
Last Update Posted (Estimate)
August 6, 2012
Last Update Submitted That Met QC Criteria
August 3, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RETRIEVE I
- G070035
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Embolism
-
Boston Scientific CorporationEKOS CorporationCompletedPulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary EmbolismUnited States
-
Inari MedicalCompletedPulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary EmbolismUnited States
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Hospital San Carlos, MadridAsociación de Cardiología Intervencionista de la Sociedad Española de CardiologíaRecruitingPulmonary Embolism | Pulmonary Embolism and Thrombosis | Pulmonary Thromboembolisms | Pulmonary Embolism Acute | Pulmonary Embolism Acute MassiveSpain
-
Inari MedicalActive, not recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
-
GlaxoSmithKlineCompleted
-
Bristol-Myers SquibbCompletedPulmonary Embolism (PE) | Pulmonary ThromboembolismUnited Kingdom
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedPulmonary Hypertension | Pulmonary ThromboembolismsSpain
-
Victor Tapson, MDBristol-Myers SquibbTerminatedPulmonary Embolism | Right Ventricular Dysfunction | Right Ventricular Failure | Pulmonary Embolism With Acute Cor Pulmonale | Pulmonary Embolism With Pulmonary Infarction | Pulmonary Embolism Subacute MassiveUnited States
-
Imperative Care, Inc.RecruitingCardiovascular Diseases | Vascular Diseases | Embolism | Thrombosis | Thromboembolism | Acute Pulmonary Embolism | Thrombus; Embolism | Emboli, PulmonaryUnited States
Clinical Trials on inferior vena cava filter
-
Crux BiomedicalCompletedPulmonary EmbolismUnited States
-
ShenZhen KYD Biomedical Technology Co., Ltd.Completed
-
Crux BiomedicalCompletedPulmonary EmbolismBelgium
-
Crux BiomedicalCompletedPulmonary EmbolismNew Zealand, Australia
-
VenitiWithdrawnDeep Vein Thrombosis | Pulmonary EmbolusNew Zealand, Australia
-
Lawson Health Research InstituteCompleted
-
C. R. BardCompletedPulmonary EmbolismUnited States
-
Group of Research in Minimally Invasive TechniquesSERVEI (Sociedad Española de Radiología Vascular e Intervencionista)Completed
-
Lifetech Scientific (Shenzhen) Co., Ltd.Unknown
-
B. Braun Interventional Systems, IncNAMSA; Bright Research PartnersCompletedPulmonary EmbolismUnited States